Acadia Pharmaceuticals Inc revenue
Acadia Pharmaceuticals Inc's revenue was $1.07bn in fiscal 2025, up 11.9% on the year before. Since fiscal 2009 ($6.4m) it has grown at a compound 37.7% a year. Over the last twelve months it was $1.14bn.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6 | 42 | 2 | 5 | 1 | 0 | 0 | 17 | 125 | 224 | 339 | 442 | 484 | 517 | 726 | 958 | 1,072 | 1,139 |
| Growth on the year before | — | +558.5% | −95.1% | +137.4% | −76.7% | −89.5% | −49.2% | +>999% | +620.7% | +79.2% | +51.5% | +30.3% | +9.6% | +6.8% | +40.4% | +31.8% | +11.9% | — |
| Gross profit | — | — | — | — | — | — | — | 14 | 116 | 211 | 328 | 432 | 473 | 507 | 685 | 876 | 983 | 1,038 |
| Gross margin | — | — | — | — | — | — | — | 82.2% | 92.7% | 94.5% | 96.7% | 97.7% | 97.8% | 98.0% | 94.3% | 91.5% | 91.7% | 91.1% |
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Acadia Pharmaceuticals Inc | $1.14bn | 11.8% | 27.4% |
| PTC Therapeutics, Inc. | $1.16bn | -35.1% | 13.1% |
| Lakefront Biotherapeutics NV | $1.26bn | 321.6% | — |
| Legend Biotech Corp | $1.03bn | 64.0% | — |
| Madrigal Pharmaceuticals, Inc. | $1.28bn | 149.0% | — |
| Kiniksa Pharmaceuticals International, plc | $946m | 58.2% | 56.1% |
Compare with peers
- PTC Therapeutics, Inc. revenue
- Lakefront Biotherapeutics NV revenue
- Legend Biotech Corp revenue
- Madrigal Pharmaceuticals, Inc. revenue
- Kiniksa Pharmaceuticals International, plc revenue
Head to head: ACAD vs PTCTACAD vs LKFTACAD vs LEGN
More: Biotechnology stocks compared, Health Care sector, rankings of US companies